Hormone replacement therapy side effects are not one list.
They depend on the exact product: estrogen-only or estrogen-plus-progestin, oral or transdermal, systemic or local, dose, duration, age, uterus status, and personal history.
The 2022 Menopause Society position statement says hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and can prevent bone loss and fracture. It also says risks differ by type, dose, duration, route, timing, and whether a progestogen is used. [1]
That is the right frame for side effects. The useful question is not "Is hormone replacement therapy safe or unsafe?" It is "Which side effects are expected, which are red flags, and does this route fit my risk profile?"
Common side effects versus serious warnings
Many hormone replacement therapy side effects are uncomfortable but not emergencies. Others should stop the conversation until a clinician evaluates them.
| Side-effect category | Examples | What to do |
|---|---|---|
| Expected nuisance effects | Breast tenderness, bloating, nausea, headache, fluid retention, mood change, spotting, or patch irritation. | Report at follow-up; dose, route, timing, or product may need adjustment. |
| Bleeding changes | New, heavy, persistent, or postmenopausal bleeding. | Evaluate bleeding instead of assuming it is normal adjustment. |
| Clot or stroke warning symptoms | One-sided leg swelling, chest pain, sudden shortness of breath, weakness, speech trouble, vision loss, or severe sudden headache. | Seek urgent evaluation. |
| Gallbladder or liver symptoms | Right-upper abdominal pain, fever, yellowing skin/eyes, dark urine, or severe nausea. | Prompt review; systemic hormones can matter for gallbladder/liver risk. |
| Breast or pelvic symptoms | New breast mass, nipple changes, pelvic pain, or unexplained bleeding. | Evaluate before continuing a casual dose-change approach. |
The FDA consumer hormone-therapy page gives a similar safety boundary. It says people should not take hormone therapy if they have problems with vaginal bleeding, certain cancers such as breast or uterine cancer, blood clot, stroke or heart attack history, bleeding disorder, liver disease, serious hormone-medicine allergy, or pregnancy. [7]
Why uterus status changes side effects
Estrogen-only therapy and estrogen-plus-progestin therapy are different decisions.
If the uterus is present, systemic estrogen usually requires endometrial protection because unopposed estrogen can stimulate the uterine lining. If the uterus has been removed, estrogen-only therapy may be discussed, but that does not remove stroke, clot, breast, heart, gallbladder, liver, age, or timing questions.
A current estradiol/norethindrone acetate label lists contraindications including undiagnosed abnormal genital bleeding, breast cancer or history of breast cancer, estrogen-dependent neoplasia, active deep vein thrombosis or pulmonary embolism or history of those conditions, active arterial thromboembolic disease such as stroke or heart attack or history of those conditions, hepatic impairment or disease, and known protein C, protein S, antithrombin deficiency, or other thrombophilic disorders. [2]
That label logic is why bleeding and uterus status belong near the top of a hormone replacement therapy side-effect discussion, not buried in fine print.
The Women's Health Initiative numbers explain the serious-risk conversation
The Women's Health Initiative estrogen-plus-progestin trial enrolled 16,608 postmenopausal women ages 50 to 79 with an intact uterus and tested conjugated equine estrogen plus medroxyprogesterone acetate versus placebo. The trial stopped after a mean 5.2 years because the global risk-benefit index supported risks exceeding benefits. [3]
Estimated hazard ratios were 1.29 for coronary heart disease, 1.26 for invasive breast cancer, 1.41 for stroke, and 2.13 for pulmonary embolism. Absolute excess risks per 10,000 person-years were 7 more coronary heart disease events, 8 more strokes, 8 more pulmonary emboli, and 8 more invasive breast cancers. Absolute reductions were 6 fewer colorectal cancers and 5 fewer hip fractures. [3]
The estrogen-alone Women's Health Initiative trial enrolled 10,739 postmenopausal women with prior hysterectomy. With conjugated equine estrogen alone, stroke risk was higher, hip-fracture risk was lower, coronary heart disease incidence was not reduced, and the global index was not significantly changed over average 6.8 years. The trial estimated 12 additional strokes and 6 fewer hip fractures per 10,000 person-years for significantly affected outcomes. [4]
The patient translation is not "all hormone replacement therapy has the same Women's Health Initiative risk." The translation is that formulation, uterus status, age, route, dose, and personal risk change the side-effect conversation.
Oral versus transdermal side effects
Route is one of the practical levers.
American College of Obstetricians and Gynecologists notes that orally administered estrogen may have a prothrombotic effect, while transdermal estrogen has little or no effect on some prothrombotic substances. American College of Obstetricians and Gynecologists says clinicians should consider possible thrombosis-sparing properties of transdermal estrogen as part of shared decision-making. [5]
A review of oral versus transdermal estrogen and venous thrombosis summarized five observational studies and reported pooled venous thromboembolism risk ratios of 1.9 for oral estrogen users and 1.0 for transdermal estrogen users. [6]
That does not mean a patch is automatically safe. It means route is chosen after eligibility. Prior clot, stroke, heart attack, estrogen-sensitive cancer, liver disease, thrombophilia, unexplained bleeding, or complex cardiovascular risk still changes the plan.
| Route or product question | Side-effect issue to review |
|---|---|
| Oral systemic estrogen | Clotting markers, triglycerides, gallbladder/liver considerations, nausea, and dose timing. |
| Transdermal estrogen | Skin irritation, adhesion, dose transfer, and whether baseline contraindications still apply. |
| Estrogen plus progestogen | Bleeding, breast tenderness, mood, sedation, endometrial protection, and progestogen-specific tolerability. |
| Local vaginal estrogen | Local irritation, discharge, and whether symptoms are isolated genitourinary syndrome of menopause rather than systemic vasomotor symptoms. |
| Compounded or pellet therapy | Dose consistency, reversibility, supraphysiologic exposure, and whether FDA-approved options were considered first. |
Red flags that should change the plan
Red flags include postmenopausal bleeding, new breast mass, chest pain, sudden shortness of breath, one-sided leg swelling, sudden weakness or speech trouble, vision loss, severe new headache, jaundice, severe abdominal pain, allergic symptoms, or pregnancy possibility.
Other side effects are not always urgent but still deserve review: persistent spotting, breast tenderness that does not settle, mood worsening, migraine pattern change, rising blood pressure, fluid retention, nausea, patch rash, hair changes, acne, or side effects after switching products.
A structured hormone assessment should identify which symptoms are expected, which need monitoring, and which mean "stop and evaluate."
What if HRT side effects make it a poor fit?
Side effects do not mean the symptom has to be ignored.
If hot flashes or night sweats are the target, the 2023 Menopause Society nonhormone statement lists evidence-supported nonhormonal options, including cognitive behavioral therapy, clinical hypnosis, selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant, and oxybutynin, depending on evidence level and fit. [8]
If vaginal dryness, painful sex, or urinary symptoms are the target, local vaginal therapy or non-estrogen genitourinary syndrome of menopause options may be a more direct discussion than systemic hormone replacement therapy.
If the main concerns are weight, hair loss, skin aging, low desire, fatigue, or mood, side effects are a clue to re-check the symptom category rather than keep adjusting hormones as if one treatment should solve every midlife change.
What to ask a clinician
Ask:
- Which side effects are expected with this exact product, route, and dose?
- Which symptoms mean urgent evaluation rather than waiting?
- If I have a uterus, how is the uterine lining protected?
- Do my age, time since menopause, clot, stroke, heart, breast, liver, migraine, or bleeding history change the plan?
- Would transdermal, lower-dose, local, or nonhormonal treatment target my symptom with less risk?
- What is the stop, switch, or reassessment rule if side effects continue?
Bottom line
Hormone replacement therapy side effects should be handled as a decision tree, not a generic warning list.
The first split is expected nuisance effects versus red flags. The second split is route, uterus status, timing, and contraindications. The third split is whether systemic hormone replacement therapy is still the best symptom-targeted treatment or whether a local or nonhormonal option fits better.
Related reading:
- Hormone Therapy After Menopause: Benefits, Risks, and Timing.
- Who Should Avoid hormone replacement therapy After Menopause?.
- Bioidentical hormone replacement therapy: FDA-Approved vs Compounded.
References
[1] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[2] DailyMed. Estradiol and norethindrone acetate tablet prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c786d6-91bd-4eea-9455-ff2abc08372f
[3] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. doi:10.1001/jama.288.3.321 https://pubmed.ncbi.nlm.nih.gov/12117397/
[4] Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-12. doi:10.1001/jama.291.14.1701 https://pubmed.ncbi.nlm.nih.gov/15082697/
[5] ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol. 2013;121(4):887-890. doi:10.1097/01.aog.0000428645.90795.d9 https://pubmed.ncbi.nlm.nih.gov/23635705/
[6] Olié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010;17(5):457-63. doi:10.1097/moh.0b013e32833c07bc https://pubmed.ncbi.nlm.nih.gov/20601871/
[7] FDA. Menopause: Medicines to Help You. https://www.fda.gov/consumers/free-publications-women/menopause-medicines-help-you
[8] New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi:10.1097/gme.0000000000002200 https://pubmed.ncbi.nlm.nih.gov/37252752/